Published in Circulation on March 15, 2004
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab (2007) 9.77
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (2008) 3.66
Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol (2006) 3.48
Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS (2010) 3.27
Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med (2014) 3.24
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS (2009) 3.08
Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS (2005) 3.07
Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood (2009) 2.92
Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation (2010) 2.71
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64
Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis (2007) 2.34
Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis (2009) 2.24
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood (2012) 2.03
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res (2009) 2.03
Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis (2012) 1.91
Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio. PLoS One (2014) 1.89
Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis (2014) 1.86
Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr (2012) 1.85
Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. Int J Clin Pract (2010) 1.68
Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS (2009) 1.67
Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab (2006) 1.67
T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis (2011) 1.64
Progression of coronary artery calcium in men affected by human immunodeficiency virus infection. Int J Cardiovasc Imaging (2011) 1.63
HIV infection and high density lipoprotein metabolism. Atherosclerosis (2007) 1.62
HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis (2012) 1.49
Brain arterial remodeling contribution to nonembolic brain infarcts in patients with HIV. Neurology (2015) 1.45
Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke (2010) 1.44
Untreated HIV infection and large and small artery elasticity. J Acquir Immune Defic Syndr (2009) 1.41
HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med (2013) 1.41
Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis (2007) 1.37
Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS (2010) 1.36
Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis (2013) 1.36
Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail (2009) 1.29
Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc (2011) 1.28
Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy. Eur Heart J (2011) 1.26
Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr (2008) 1.25
Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr (2015) 1.25
Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. J Am Heart Assoc (2012) 1.25
Dyslipidemia and its Treatment in HIV Infection. Top HIV Med (2010) 1.24
Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS (2007) 1.22
The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS (2012) 1.21
Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr (2009) 1.20
Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis (2011) 1.18
Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord (2009) 1.13
A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection. J Acquir Immune Defic Syndr (2012) 1.09
A genome-wide association study of carotid atherosclerosis in HIV-infected men. AIDS (2010) 1.08
Progression of carotid intima-media thickness and coronary artery calcium over 6 years in an HIV-infected cohort. J Acquir Immune Defic Syndr (2013) 1.08
Is HIV-1 infection associated with endothelial dysfunction in a population of African ancestry in South Africa? Cardiovasc J Afr (2011) 1.07
Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain. J Neurovirol (2010) 1.07
Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis (2010) 1.05
Infectious burden and atherosclerosis: A clinical issue. World J Clin Cases (2014) 1.02
Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age. Clin Neuropsychol (2010) 1.02
Subclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda. PLoS One (2014) 1.01
Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV study. Atherosclerosis (2012) 1.01
Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study. AIDS (2009) 0.99
CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection. Clin Infect Dis (2015) 0.99
Association of HIV viral load with monocyte chemoattractant protein-1 and atherosclerosis burden measured by magnetic resonance imaging. AIDS (2009) 0.99
A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. AIDS (2012) 0.98
Increased coronary vessel wall thickness in HIV-infected young adults. Clin Infect Dis (2014) 0.97
The contribution of HIV infection to intracranial arterial remodeling: a pilot study. Neuropathology (2012) 0.97
Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol (2011) 0.96
The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS (2009) 0.96
Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr Opin HIV AIDS (2014) 0.96
Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. Int J Vasc Med (2011) 0.95
Arterial disease in patients with human immunodeficiency virus infection: what has imaging taught us? JACC Cardiovasc Imaging (2014) 0.95
Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease? Curr Opin HIV AIDS (2014) 0.94
The Relationship Between HIV Infection and Cardiovascular Disease. Curr Cardiol Rev (2008) 0.94
Effects of aging and smoking on carotid intima-media thickness in HIV-infection. AIDS (2013) 0.93
HIV Infection Is Associated With Progression of Subclinical Carotid Atherosclerosis. Clin Infect Dis (2015) 0.93
Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort. Neurology (2014) 0.92
Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun (2014) 0.92
Focus on the heart: alcohol consumption, HIV infection, and cardiovascular disease. Alcohol Res Health (2010) 0.91
Platelet decline as a predictor of brain injury in HIV infection. J Neurovirol (2011) 0.91
Interleukin-18 predicts atherosclerosis progression in SIV-infected and uninfected rhesus monkeys (Macaca mulatta) on a high-fat/high-cholesterol diet. Lab Invest (2009) 0.91
Surface roughness detection of arteries via texture analysis of ultrasound images for early diagnosis of atherosclerosis. PLoS One (2013) 0.90
Prehypertension, hypertension, and the risk of acute myocardial infarction in HIV-infected and -uninfected veterans. Clin Infect Dis (2013) 0.90
Effect of inter-reader variability on outcomes in studies using carotid intima media thickness quantified by carotid ultrasonography. Eur J Epidemiol (2010) 0.89
Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon. Vasc Health Risk Manag (2013) 0.88
Clinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection: a systematic review. Virulence (2013) 0.87
The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study. Atherosclerosis (2013) 0.87
Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients. Clin Infect Dis (2013) 0.85
Elevated levels of asymmetric dimethylarginine are associated with lower CD4+ count and higher viral load in HIV-infected individuals. Atherosclerosis (2013) 0.84
HIV infection and cardiovascular risk in black South Africans. Cardiovasc J Afr (2011) 0.84
Endothelial dysfunction, arterial stiffening, and intima-media thickening in large arteries from HIV-1 transgenic mice. Ann Biomed Eng (2012) 0.83
Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. BMC Infect Dis (2015) 0.83
HIV-1, reactive oxygen species, and vascular complications. Free Radic Biol Med (2012) 0.83
Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: a prospective study. Inflammation (2012) 0.83
Human immunodeficiency virus & cardiovascular risk. Indian J Med Res (2011) 0.83
A prospective cohort study of periodontal disease measures and cardiovascular disease markers in HIV-infected adults. AIDS Res Hum Retroviruses (2011) 0.83
Risk factors for subclinical atherosclerosis in HIV-infected patients under and over 40 years: a case-control study. BMC Infect Dis (2013) 0.83
The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial. PLoS Med (2016) 0.83
Psychological factors, including alexithymia, in the prediction of cardiovascular risk in HIV infected patients: results of a cohort study. PLoS One (2013) 0.83
Carotid intima-media thickness is increased in subjects with ischemic heart disease having a familial incidence. Exp Clin Cardiol (2006) 0.82
Echocardiography and carotid intima-media thickness among asymptomatic HIV-infected adolescents in Thailand. AIDS (2014) 0.82
T-cell activation, both pre- and post-HAART levels, correlates with carotid artery stiffness over 6.5 years among HIV-infected women in the WIHS. J Acquir Immune Defic Syndr (2014) 0.82
Cardiovascular and Endothelial Disease in HIV Infection. Curr Infect Dis Rep (2005) 0.82
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia. PLoS One (2015) 0.81
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis (2003) 8.00
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA (2006) 7.14
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood (2004) 7.09
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis (2008) 6.03
Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA (2008) 5.68
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (2006) 5.67
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. Circulation (2012) 5.25
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (2004) 4.64
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr (2010) 4.20
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med (2010) 4.07
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol (2005) 3.96
Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis (2009) 3.91
Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med (2006) 3.90
Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep (2010) 3.80
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem (2009) 3.71
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS (2006) 3.70
Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature (2010) 3.57
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother (2004) 3.48
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis (2011) 3.38
CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol (2007) 3.31
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA (2006) 3.20
Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS One (2008) 3.19
Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation (2010) 3.17
Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One (2008) 3.13
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS (2009) 3.08
Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab (2007) 3.05
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation (2011) 3.01
Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr (2009) 2.99
Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS (2006) 2.98
Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation (2002) 2.97
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med (2008) 2.94
Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic. JAMA (2002) 2.91
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation (2015) 2.84
Antiretroviral therapy and management of HIV infection. Lancet (2010) 2.84
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood (2013) 2.72
Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation (2010) 2.71
Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep (2007) 2.68
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS (2003) 2.66
High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (2003) 2.65
Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS (2012) 2.65
Food insecurity is associated with morbidity and patterns of healthcare utilization among HIV-infected individuals in a resource-poor setting. AIDS (2012) 2.63
Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J Mol Diagn (2011) 2.57
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis (2011) 2.56
History-adjusted marginal structural models for estimating time-varying effect modification. Am J Epidemiol (2007) 2.56